The Patent Finder
BT

Beam Therapeutics Inc.

First filing 2020
OverviewNotableFeesChangesFamiliesPatent listSources & methods

19 patents currently held

2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
5 more records may belong here and await a decision; they are not counted.

The next term ends in Feb 2040. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Feb 2040
Next term end
16
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents all others Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Mar 12, 2027
    The maintenance fee for Compositions and Methods for Treating Hemoglobinopathies (US 11,752,202) comes due Mar 12, 2027. Unpaid by Sep 13, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 3 of the patents on this record were granted since Aug 18, 2026

What they patent

The 5 largest of its 16 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.
PatentTitleStatusExpiresConfidence
US 11,142,760Compositions and Methods for Treating Hemoglobinopathies
In force
 · Medium confidence
In forceMedium confidence
US 11,155,803Adenosine Deaminase Base Editors and Methods of Using Same to Modify a Nucleobase in a Target Sequence
In force
 · Low confidence
In forceLow confidence
US 11,344,609Compositions and Methods for Treating Hemoglobinopathies
In force
 · Medium confidence
In forceMedium confidence
US 11,752,202Compositions and Methods for Treating Hemoglobinopathies
In force
 · Low confidence
In forceLow confidence
US 12,016,908Compositions and Methods for Treating Hemoglobinopathies
In force
 · Low confidence
In forceLow confidence
US 12,622,931Compositions and Methods for Treating ALPHA-1 Antitrypsin Deficiency
In force
 · Medium confidence
In forceMedium confidence
US 12,125,145Systems and Methods for Implemented Mixed Reality in Laboratory Automation
In force
 · High confidence
In forceHigh confidence
US 12,600,971Modified Immune Cells Having Adenosine Deaminase Base Editors for Modifying a Nucleobase in a Target Sequence
In force
 · High confidence
In forceHigh confidence
US 12,767,959Nucleobase Editors Having Reduced Off-Target Deamination and Methods of Using Same to Modify a Nucleobase Target Sequence
In force
 · High confidence
In forceHigh confidence
US 12,133,884Methods of Substituting Pathogenic Amino Acids Using Programmable Base Editor Systems
In force
 · High confidence
In forceHigh confidence
10 of 19 patents shown.
Pro members see all 19.
Pro members: see all 19 patents
Also on record, not counted in the 19: 2 patents in force now held by others · 87 applications pending · 2 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited